Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
L. W. Vestermark
Observed names:
L. Vestermark,
L.W. Vestermark,
LW Vestermark,
Vestermark, L.
Institution:
Odense University Hospital
Observed institutions:
Danish Medicines Agency,
Odense University Hospital
OpenAlex ID:
A5006731302
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
2015
·
H. Hagman
, J.-E. Frödin
, et al.
·
Annals of Oncology
·
56
PDF
LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)
2022
·
R. Salazar
, S. Tafuto
, et al.
·
Annals of Oncology
·
36
PDF
UFT (tegafur–uracil) in rectal cancer
2008
·
E. Casado
, P. Pfeiffer
, et al.
·
Annals of Oncology
·
24
PDF
Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer
2009
·
J. K. Bjerregaard
, K. R. Schønnemann
, et al.
·
Journal of Clinical Oncology
·
11
NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms
2024
·
H. Sorbye
, G. O. Hjortland
, et al.
·
Journal of Neuroendocrinology
·
9
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial
2025
·
J. Capdevila
, S. Tafuto
, et al.
·
ESMO Open
·
8
PDF
A national cohort study of long‐course preoperative radiotherapy in primary fixed rectal cancer in Denmark
2009
·
S. Bülow
, L. H. Jensen
, et al.
·
Colorectal Disease
·
6
A Randomized Study of Kras-Stratified Maintenance Therapy with Bevacizumab, Erlotinib or Metronomic Capecitabine After First Line Induction Treatment of Metastatic Colorectal Cancer: the Nordic Act2 Trial
2014
·
H. Hagman
, J. Frödin
, et al.
·
Annals of Oncology
·
2
A Phase II Study of Thalidomide and Temozolomide in Patients With Brain Metastases From Malignant Melanoma. Lymphopenia Correlates With Response
2008
·
L.W. Vestermark
, E Holtved
, et al.
·
ecancermedicalscience
·
2
PDF
A Consensus Developed Morphological Re-evaluation of 196 Cases with Metastatic High-grade Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN G3) from the Nordic NEC Registries: Consequences for Classification, Treatment Response and Survival
2019
·
Elvebakken, H.
, Perren, A.
, et al.
·
Research at the University of Copenhagen (University of Copenhagen)
·
1
847P Molecular-clinical characteristics and treatment outcome for metastatic colorectal neuroendocrine carcinomas and adenocarcinomas: A comparison of two population-based prospective cohorts
2025
·
S. Morken
, S.W. Langer
, et al.
·
Annals of Oncology
Author response for " NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms"
2024
·
H. Sorbye
, G. O. Hjortland
, et al.
·
Publons reviews and discussion
Triple Chemotherapy (DOX) in Patients with Advanced Gastro-Esophageal Adenocarcinoma - A Phase II Study
2021
·
LS Tarpgaard
, M Jensen
, et al.
·
International Journal of Cancer and Clinical Research
PDF
Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas : A Nordic Multicenter Study
2017
·
Renate Galleberg
, Ulrich Knigge
, et al.
·
Research at the University of Copenhagen (University of Copenhagen)
P-070 Phase I dose-finding study of S-1 in combination with docetaxel and oxaliplatin (DOS) as first-line therapy in patients with advanced gastro-esophageal cancer
2015
·
L. Vestermark
, H. Jensen
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
15
Citation count:
155
H-index:
6
I10-index:
4
Year
Topic
Type